Results 21 to 30 of about 366,991 (303)

Cisplatin decreases HOXA13 and alphaVBeta3 integrin levels in the uterus

Taiwanese Journal of Obstetrics & Gynecology, 2021
Objective: To examine the effects of cisplatin on uterine histology and implantation molecules and the possible protective role of recombinant Klotho administration on uterine histology and uterine receptivity in mice exposed to cisplatin.
Mustafa Albayrak, Ismail Biyik, Fikriye Yasemin Ozatik, Orhan Ozatik, Neziha Senem Ari, Yasemin Teksen, Ozlem Erten   +6 more
doaj   +1 more source

Genetic and Modifiable Risk Factors Contributing to Cisplatin-Induced Toxicities [PDF]

, 2019
Effective administration of traditional cytotoxic chemotherapy is often limited by off-target toxicities. This clinical dilemma is epitomized by cisplatin, a platinating agent that has potent antineoplastic activity due to its affinity for DNA and other ...
Dinh, Paul C. Jr., Dolan, M., El Charif, Omar, Travis, Lois B., Trendowski, Matthew R.   +4 more
core   +1 more source

Equine sarcoids: Bovine Papillomavirus type 1 transformed fibroblasts are sensitive to cisplatin and UVB induced apoptosis and show aberrant expression of p53 [PDF]

, 2012
Bovine papillomavirus type 1 infects not only cattle but also equids and is a causative factor in the pathogenesis of commonly occurring equine sarcoid tumours.
Campo, M., Finlay, M., Morgan, I.M., Nasir, L., Yuan, Z.   +4 more
core   +3 more sources

Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line

BMC Cancer, 2006
Background Cisplatin is widely used for chemotherapy of head and neck squamous cell carcinoma. However, details of the molecular mechanism responsible for cisplatin resistance are still unclear.
Zhang Ping, Zhang Zhiyuan, Zhou Xiaojian, Qiu Weiliu, Chen Fangan, Chen Wantao   +5 more
doaj   +1 more source

Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells [PDF]

, 2010
Inhibition or downregulation of Bcl-2 represents a new therapeutic approach to by-pass chemoresistance in cancer cells. Therefore, we explored the potential of this approach in breast cancer cells.
A Letai, AK Zimmermann, Cagri Bodur, D Moon, D Tian, Dilek Telci, DJ Stewart, Elif Damla Arisan, F Manero, FA Sinicrope, Huveyda Basaga, IJ Enyedy, J An, J Chen, J Skommer, J Yu, JC Reed, JD Lickliter, JI Okani, JL Wang, JL Wang, L Chen, L Ming, L Oliver, M Milella, Ozgur Kutuk, RK Srivastava, SW Lowe, Tugsan Tezil, X Pei, X Wang, XY Pei, Y Ling, Y Su, Z Liu   +34 more
core   +1 more source

The Effect of Bone Marrow Transplantation on Oocyte-Granulosa Cell Interaction and Follicular Development of Cisplatin-Induced Ovarian Failure in Rat

Journal of Stem Cell Research and Tissue Engineering, 2021
Introduction: Chemotherapy has cytotoxic effect that induces follicular damage and abnormal folliculogenesis leads to ovarian failure. Two crucial   growth factors in abnormal folliculogenesis, Growth Differentiation Factor-9 (GDF-9) and Kit-Ligand, will
hendi hendarto
doaj   +1 more source

Cisplatin Nephrotoxicity

American Journal of Kidney Diseases, 1986
Cis-dichlorodiammine platinum (II), or cisplatin, has emerged as a principal chemotherapeutic agent in the treatment of otherwise resistant solid tumors and is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity, which has made it necessary both to lower its dosage and
R, Safirstein, J, Winston, M, Goldstein, D, Moel, S, Dikman, J, Guttenplan   +5 more
openaire   +2 more sources

New trends for metal complexes with anticancer activity [PDF]

, 2008
Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. This has, for instance, led to the clinical application of chemotherapeutic agents for cancer treatment, such as cisplatin. The use of cisplatin is,
Ang, Ang, Barnard, Barnes, Bednarski, Bergamo, Bregman, Calderone, Casini, Debreczeni, Dixon, Dyson, Failes, Feazell, Guo, Habtemariam, Hall, Hambley, Hannon, Harris, Heringova, Hillard, Hotze, James, Jung, Komeda, Liu, Lutterman, MacDiarmid, Mackay, Mackay, McNae, Meggers, Milacic, Noor, Oleksi, Orvig, Ott, Pascu, Peacock, Peter J Sadler, Pieter CA Bruijnincx, Reed, Schatzschneider, Schlawe, Scolaro, Smalley, Sun, Thompson, Timerbaev, Urig, Urig, van Zutphen, Wang, Weidt, Yan, Yang   +56 more
core   +1 more source

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Molecular Cancer, 2022
Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhen-duo Shi, Lin Hao, Xiao-xiao Han, Zhuo-Xun Wu, Kun Pang, Yang Dong, Jia-xin Qin, Guang-yue Wang, Xuan-ming Zhang, Tian Xia, Qing Liang, Yan Zhao, Rui Li, Shao-qi Zhang, Jun-hao Zhang, Jian-gang Chen, Gong-cheng Wang, Zhe-Sheng Chen, Cong-hui Han   +18 more
doaj   +1 more source

Cisplatin Nanocapsules

, 2005
Cisplatin nanocapsules represent a novel lipid formulation of the anticancer drug cis-diamminedichloroplatinum(II), in which nanoprecipitates of cisplatin are covered by a phospholipid bilayer coat consisting of an equimolar mixture of phosphatidylcholine and phosphatidylserine.
de Kroon, A.I.P.M., Staffhorst, R.W.H.M., de Kruijff, B., Burger, K.N.J.   +3 more
openaire   +4 more sources